India’s pharmaceutical industry is the world’s largest generic drug supplier by volume, accounting for approximately 20 percent of global generic medicine exports and exporting to over 200 countries. The Indian pharmaceutical market was valued at approximately USD 50 billion in 2025 and is projected to reach USD 130 billion by 2030, growing at a CAGR of around 11 percent. India supplies 50 percent of Africa’s vaccine needs, 40 percent of the US generic drug market, and 25 percent of all medicines used by the UK. With over 3,000 pharma companies and 10,500 manufacturing facilities, India’s pharma ecosystem is the backbone of global affordable healthcare. Sun Pharmaceutical Industries is India’s largest pharma company with revenues of Rs 50,084 crore in FY2025. Let us have a look at the top 10 pharma companies in India for the year 2026.
1. Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries, founded in the year 1983 by Dilip Shanghvi with a capital of just Rs 10,000 in Vapi, Gujarat, is India’s largest and most globally diversified pharmaceutical company with FY2025 revenue of Rs 50,084 crore and a presence in over 100 countries. The company is the fourth largest specialty generic pharma company in the world and the largest in India, with a strong focus on specialty branded formulations in dermatology, ophthalmology, oncology, and CNS. Sun Pharma’s key brands include Absorica, Ilumya, Cequa, and Winlevi globally and Volini, Pantodac, and Strocit in India.
Sun Pharma serves patients, hospitals, and healthcare providers globally with branded specialty medicines, generic formulations, active pharmaceutical ingredients, and over-the-counter products, and is the most internationally diversified Indian pharma company with its US business alone contributing over 30 percent of revenues.
2. Cipla Limited
Cipla Limited, founded in the year 1935 by Dr. K.A. Hamied in Mumbai, is one of India’s most respected and iconic pharmaceutical companies with a FY2025 revenue of approximately Rs 27,000 crore. The company gained international recognition in 2001 when it offered HIV antiretroviral drugs to Africa at less than 1 dollar a day — a decision that transformed global access to AIDS medicines. Cipla operates across prescription medicines, consumer health, and biosimilars with a strong presence in the US, South Africa, India, and over 80 other countries.
Cipla serves patients and healthcare providers across India and globally with a wide range of respiratory, anti-infective, cardiovascular, oncology, and consumer health products, and is universally recognised as the company that democratised access to life-saving medicines for millions of people across the developing world.
3. Dr. Reddy’s Laboratories Limited
Dr. Reddy’s Laboratories, founded in the year 1984 by Dr. K. Anji Reddy in Hyderabad, is one of India’s most globally significant pharmaceutical companies with FY2025 revenues of approximately Rs 32,000 crore and a presence in over 66 countries. The company is a global leader in generics and active pharmaceutical ingredients and has been building a strong proprietary product pipeline in branded specialties, biosimilars, and complex generics. Dr. Reddy’s PSAI business is one of the world’s leading API manufacturers supplying pharmaceutical-grade ingredients to global drug makers.
Dr. Reddy’s serves global pharmaceutical markets across generics, branded formulations, biologics, APIs, and custom pharmaceutical services, and is the most export-intensive among India’s large pharma companies with North America and Europe collectively contributing more than 50 percent of its revenues.
4. Divi’s Laboratories Limited
Divi’s Laboratories, founded in the year 1990 by Dr. Murali Divi and headquartered in Hyderabad, is one of India’s most profitable and globally respected active pharmaceutical ingredient and contract manufacturing companies. The company is the global market leader in several key API molecules including Naproxen, Dextromethorphan, Gabapentin, and several nutraceuticals. Divi’s operates state-of-the-art manufacturing facilities in Hyderabad and Visakhapatnam and exports over 95 percent of its production to major pharmaceutical companies in Europe, the USA, and Japan.
Divi’s Laboratories serves global innovator pharmaceutical companies and generic drug manufacturers with high-purity active pharmaceutical ingredients and contract synthesis services, and is the trusted long-term API partner for many of the world’s largest pharmaceutical companies who rely on Divi’s quality, scale, and intellectual property compliance.
5. Aurobindo Pharma Limited
Aurobindo Pharma, founded in the year 1986 and headquartered in Hyderabad, is one of India’s largest and most globally present pharmaceutical manufacturers with FY2025 revenue exceeding Rs 29,000 crore and a product portfolio of over 600 consolidate filings in 150 countries. The company is among the top five generic pharmaceutical companies in the United States by prescription volume and has a strong presence in Europe through its Apotex Netherlands acquisition. Aurobindo’s integrated API-to-formulation manufacturing model gives it significant cost advantages.
Aurobindo Pharma serves global generic pharmaceutical markets across the USA, Europe, emerging markets, and India with a comprehensive range of solid oral dosage forms, injectables, APIs, and biosimilars, and is one of the most vertically integrated pharmaceutical manufacturers in the world with captive API production for over 65 percent of its formulation requirements.
6. Lupin Limited
Lupin Limited, founded in the year 1968 by Dr. Desh Bandhu Gupta in Mumbai, is one of India’s most respected pharmaceutical companies with FY2025 revenues of approximately Rs 23,000 crore and a presence in over 100 countries. The company is the third largest pharmaceutical company in the United States by prescriptions and holds market-leading positions in respiratory, cardiovascular, anti-diabetic, and anti-infective therapeutic categories globally. Lupin’s biosimilars pipeline and its inhalation franchise are two of its most strategically important growth engines for the next decade.
Lupin serves global patients and healthcare providers with complex generic formulations, branded drugs, APIs, and biosimilars across North America, Europe, Asia Pacific, and India, and is the most dominant Indian pharma company in the anti-tuberculosis segment globally through its flagship drug brands.
7. Torrent Pharmaceuticals Limited
Torrent Pharmaceuticals, founded in the year 1959 as Trinity Laboratories and part of the Torrent Group headquartered in Ahmedabad, is one of India’s most focused and profitable pharma companies with FY2025 revenue of approximately Rs 11,600 crore and market leadership in cardiovascular, CNS, gastrointestinal, and women’s health therapeutic categories. The company’s flagship brand Shelcal is India’s largest-selling calcium supplement and its domestic branded formulations business is one of the strongest in the industry with a highly productive field force.
Torrent Pharmaceuticals serves patients and healthcare providers across India, Germany, Brazil, and the USA with a focused portfolio of branded and generic formulations in its chosen therapeutic areas, and is recognised for the exceptional productivity of its field force and the depth of its prescription brand building in the Indian pharmaceutical market.
8. Alkem Laboratories Limited
Alkem Laboratories, founded in the year 1973 and headquartered in Mumbai, is one of India’s most consistently growing pharmaceutical companies with FY2025 revenue of approximately Rs 14,000 crore and a dominant position in the Indian domestic pharmaceutical market where it ranks among the top 5 companies by prescription market share. The company has strong market leadership in anti-infective, CNS, gastrointestinal, and pain management therapeutic categories in India and is steadily expanding its US generics business as a second growth engine.
Alkem Laboratories serves Indian patients and healthcare providers with a wide range of branded generic formulations across therapeutic categories and is growing its US generics portfolio as a diversification strategy, leveraging its strong domestic branded business cashflows to fund international market expansion.
9. Zydus Lifesciences Limited
Zydus Lifesciences, formerly known as Cadila Healthcare and founded in the year 1952 by Ramanbhai Patel in Ahmedabad, is one of India’s most innovative pharmaceutical companies with FY2025 revenue of approximately Rs 20,000 crore. The company achieved a historic milestone in 2021 by developing ZyCoV-D — the world’s first DNA plasmid vaccine for COVID-19 — demonstrating its innovative capability. Zydus has a strong presence in the US generics market, an expanding biosimilars portfolio, and growing revenue from its new chemical entity research pipeline.
Zydus Lifesciences serves patients and healthcare providers in India, the USA, and emerging markets with branded and generic formulations, biosimilars, vaccines, and consumer wellness products, and is among the most research-intensive Indian pharmaceutical companies investing significantly in new drug development.
10. Abbott India Limited
Abbott India Limited, a subsidiary of the American multinational Abbott Laboratories which was founded in the year 1888, is one of India’s largest and most trusted pharmaceutical companies in the branded prescription medicines segment. The company’s Indian portfolio includes some of India’s most recognised and highest-prescribed pharmaceutical brands including Cremalax, Thyronorm, Duphaston, and Udiliv across women’s health, thyroid, gastroenterology, and metabolic disorders. Abbott India consistently ranks among the top pharmaceutical companies in India by domestic prescription market share.
Abbott India serves Indian patients and healthcare providers with a portfolio of established and trusted branded pharmaceutical products across its chosen therapeutic areas, and benefits from the global Abbott parent’s research capabilities, quality standards, and supply chain strength that give it a significant competitive advantage in India’s branded pharmaceutical market.
Frequently Asked Questions (FAQs)
Q: Which is the largest pharma company in India in 2026?
A: Sun Pharmaceutical Industries is India’s largest pharma company with FY2025 revenue of Rs 50,084 crore, making it the fourth largest specialty generic pharmaceutical company in the world. It is followed by Dr. Reddy’s Laboratories at approximately Rs 32,000 crore and Cipla at approximately Rs 27,000 crore in revenue terms.
Q: What is India’s share in global pharmaceutical exports?
A: India accounts for approximately 20 percent of global generic medicine exports by volume, supplies 50 percent of Africa’s vaccine needs, 40 percent of the US generic drug market, and 25 percent of all medicines used by the UK. India exports pharmaceutical products to over 200 countries and is universally recognised as the pharmacy of the world.
Q: What is the difference between branded and generic pharmaceuticals?
A: A branded pharmaceutical is a new drug developed by a research company, patented, and sold under a brand name at a premium price. Once the patent expires, other companies can manufacture and sell the same molecule under its generic chemical name at a significantly lower price. Indian pharma companies are global leaders in producing high-quality generic versions of patented medicines that make healthcare affordable worldwide.
Q: What is the growth outlook for India’s pharma industry?
A: India’s pharma market is projected to grow from approximately USD 50 billion in 2025 to USD 130 billion by 2030 at a CAGR of around 11 percent. Key growth drivers include rising domestic healthcare expenditure, increasing chronic disease prevalence, government health insurance expansion through Ayushman Bharat, biosimilar development, and new US FDA-approved product launches by Indian companies in the American generic market.
Q: What is the India Pharmaceutical Mission and how does it support the industry?
A: The Production Linked Incentive scheme for pharmaceuticals was launched by the Indian government to boost domestic manufacturing of complex medicines, API ingredients, and medical devices. The PLI scheme provides financial incentives to pharmaceutical companies that achieve defined production targets in specified product categories, reducing India’s import dependence on APIs from China and strengthening the country’s pharmaceutical supply chain resilience.
